Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recruiting

Phase 1

M1774 & ZEN-3694Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05950464

Conditions

Recurrent Endometrial Carcinoma

Recurrent Endometrial Clear Cell Adenocarcinoma

Recurrent Endometrial Endometrioid Adenocarcinoma

Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma

Recurrent Ovarian Clear Cell Adenocarcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BET Bromodomain Inhibitor ZEN-3694

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Electrocardiography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-03. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-02-27.